Blood Cancer Drugs Global Market Report 2026

Blood cancer drugs are medications used to treat blood cancer by harnessing the body's immune system to combat the disease and slow down the growth of cancer cells. Chemotherapy, biological therapy, targeted therapy, radiation therapy, and stem cell transplants are some of the commonly used treatments for blood cancer.

The main types of blood cancer drugs are for leukemia and lymphoma. Leukemia is a cancer of the blood-forming tissues that affects the bone marrow and lymphatic system. The different types of drugs include Rituxan/MabThera (rituximab), Gleevec/Glivec (imatinib), Revlimid (lenalidomide), Velcade (bortezomib), Tasigna (nilotinib), Pomalyst (pomalidomide), Fidanza (azacitidine), Kyprolis (carfilzomib), Adcetris (brentuximab vedotin), among others, and involve various treatment approaches such as chemotherapeutics, monoclonal antibodies/targeted therapies, and immunotherapeutics.

Tariffs have increased the cost of imported oncology APIs and biologics used in the manufacturing of blood cancer therapies. These impacts are most pronounced in North America and Europe, where advanced oncology production depends on global supply networks. Rising tariff related expenses have placed pressure on manufacturing economics and pricing strategies for critical hematologic drugs. This has influenced procurement decisions and capacity planning across hospital and specialty care settings. However, tariffs are also supporting domestic production of critical blood cancer drugs, local biologics manufacturing, and stronger regional supply chain resilience over the long term.

The blood cancer drugs market research report is one of a series of new reports from The Business Research Company that provides blood cancer drugs market statistics, including blood cancer drugs industry global market size, regional shares, competitors with a blood cancer drugs market share, detailed blood cancer drugs market segments, market trends and opportunities, and any further data you may need to thrive in the blood cancer drugs industry. This blood cancer drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The blood cancer drugs market size has grown strongly in recent years. It will grow from $79.6 billion in 2025 to $84.59 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to increasing leukemia and lymphoma prevalence, long-standing chemotherapy usage, expansion of oncology hospitals, availability of monoclonal antibodies, improved diagnostic capabilities.

The blood cancer drugs market size is expected to see strong growth in the next few years. It will grow to $111.86 billion in 2030 at a compound annual growth rate (CAGR) of 7.2%. The growth in the forecast period can be attributed to growth in precision oncology, increasing adoption of stem cell therapies, innovation in biologics, rising healthcare expenditure, expansion of cancer screening programs. Major trends in the forecast period include rising adoption of targeted blood cancer therapies, growing use of immunotherapy in hematologic malignancies, expansion of combination treatment approaches, increasing focus on personalized cancer treatment, improved survival outcomes in blood cancer patients.

The rising incidence of blood cancer cases worldwide is anticipated to propel the growth of the blood cancer drug market in the coming years. Blood cancer encompasses a group of malignant disorders, including leukemia, lymphoma, and myeloma, which impact the blood and bone marrow and necessitate long-term, specialized treatments such as chemotherapy, immunotherapy, targeted therapies, and stem cell transplantation. This increase in disease prevalence is driven by factors like aging populations, genetic mutations, environmental exposures, and lifestyle-related risks. The growing number of blood cancer cases is fueling demand for advanced blood cancer drugs that provide better survival outcomes, reduced side effects, improved patient quality of life, and personalized treatment approaches. For example, in October 2025, according to Blood Cancer United, a US-based blood cancer information and advocacy organization, an estimated 66,890 individuals were expected to be diagnosed with leukemia, with around 475,323 people living with or in remission from the disease in the United States, and approximately 23,540 deaths projected to result from leukemia in 2025. Consequently, the rising global incidence of blood cancer cases is driving the expansion of the blood cancer drug market.

Major companies operating in the blood cancer drugs market are concentrating on developing new therapies and pursuing FDA approval to strengthen their position in the market. FDA approval for drugs refers to the official authorization granted by the United States Food and Drug Administration (FDA) allowing a pharmaceutical product to be legally marketed and sold within the United States. For example, in March 2024, Bristol Myers Squibb, a US-based pharmaceutical company, obtained FDA approval for its first and only CAR T-cell therapy for adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). This accelerated approval permits its use in patients who have undergone at least two prior treatments, including a Bruton tyrosine kinase inhibitor and a B-cell lymphoma 2 inhibitor. According to the TRANSCEND CLL 004 trial, Breyanzi showed a 20% complete response rate and a median duration of response of 35.3 months among responders.

In May 2025, Helix Biopharma, a biopharmaceutical company based in Canada, acquired Laevoroc Immunology AG and Laevoroc Chemotherapy AG for an undisclosed sum. Through this acquisition, Helix Biopharma intends to enhance its blood cancer drug portfolio by incorporating these novel oncology candidates into its pipeline, facilitating the development of innovative therapies for hematologic malignancies. Laevoroc Group is a Canadian biotechnology company focused on early-stage oncology drug candidates, with a strong history in preclinical research and development.

Major companies operating in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Eli Lilly and Company Inc., Johnson & Johnson, Novartis AG, Pfizer Inc., AbbVie Inc., Takeda Pharmaceutical Company Limited, F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Astellas Pharma Inc., Merck & Co. Inc., Gilead Sciences Inc., Sanofi S.A., Eisai Co. Ltd., Jazz Pharmaceuticals plc, Kyowa Kirin Co. Ltd., Menarini Group, Millennium Pharmaceuticals Inc., Mundipharma International Limited, Mylan N.V., Ono Pharmaceutical Co. Ltd., Otsuka Pharmaceutical Co. Ltd., Pharmacyclics LLC, Seattle Genetics Inc., Servier Laboratories, Shire plc, Spectrum Pharmaceuticals Inc., Taiho Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., Tolero Pharmaceuticals Inc., UCB S.A.

North America was the largest region in the blood cancer drugs market in 2025. Middle East is expected to be the fastest-growing region in the blood cancer drugs market during the forecast period. The regions covered in the blood cancer drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the blood cancer drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The blood cancer drugs market consists of sales Altretamine, Bendamustine, Bendamustine, and Carboplatin. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Blood Cancer Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses blood cancer drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for blood cancer drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The blood cancer drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Blood Cancer Type: Leukemia; Lymphoma
• 2) By Drugs: Rituxan Or Mabthera (Rituximab); Gleevec Or Glivec (Imatinib); Revlimid (Lenalidomide); Velcade (Bortezomib); Tasigna (Nilotinib); Pomalyst (Pomalidomide); Vidaza (Azacitidine); Kyprolis (Carfilzomib); Adcetris (Brentuximab Vedotin); Other Drugs
• 3) By Treatment Approaches: Chemotherapeutic; MAbs/Targeted Therapies; Immunotherapeutic
• Subsegments:
• 1) By Leukemia: Acute Lymphoblastic Leukemia (ALL); Chronic Lymphocytic Leukemia (CLL); Acute Myeloid Leukemia (AML); Chronic Myeloid Leukemia (CML); Other Types of Leukemia
• 2) By Lymphoma: Hodgkin Lymphoma; Non-Hodgkin Lymphoma (NHL); Burkitt Lymphoma; Follicular Lymphoma; Mantle Cell Lymphoma; Other Types of Lymphoma
• Companies Mentioned: Amgen Inc.; AstraZeneca PLC; Bayer AG; Eli Lilly and Company Inc.; Johnson & Johnson; Novartis AG; Pfizer Inc.; AbbVie Inc.; Takeda Pharmaceutical Company Limited; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; Astellas Pharma Inc.; Merck & Co. Inc.; Gilead Sciences Inc.; Sanofi S.A.; Eisai Co. Ltd.; Jazz Pharmaceuticals plc; Kyowa Kirin Co. Ltd.; Menarini Group; Millennium Pharmaceuticals Inc.; Mundipharma International Limited; Mylan N.V.; Ono Pharmaceutical Co. Ltd.; Otsuka Pharmaceutical Co. Ltd.; Pharmacyclics LLC; Seattle Genetics Inc.; Servier Laboratories; Shire plc; Spectrum Pharmaceuticals Inc.; Taiho Pharmaceutical Co. Ltd.; Teva Pharmaceutical Industries Ltd.; Tolero Pharmaceuticals Inc.; UCB S.A.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.